Revvity Q3 FY2026: adjusted EPS $1.38 tops consensus, guidance raised
Revvity beat the consensus EPS number and raised full-year guidance, so this reads as a clean beat-and-raise. Revenue of $728.9 million grew 4.3% on a reported basis and 7% pro forma, while adjusted EPS of $1.38 came in 4.1% above the $1.3258 estimate. The catch is that the beat leans on margin expansion and cost control rather than a big top-line surprise.
1 · Expected vs. Actual
Free preview belowGAAP EPS rose to $0.56 from $0.41, but the number most investors track is adjusted EPS of $1.38, which beat the $1.3258 consensus by 4.1%. The gap between the two is mostly $84.7 million of intangible amortization and $28.4 million of restructuring charges, so the GAAP profit line looks thin next to the adjusted one. That is not new for Revvity, but it means the headline number depends on what you exclude.
Revenue was $728.9 million versus $698.9 million a year ago, up 4.3%, and the pro forma figure of $709.6 million grew 7.4% from $660.5 million. Life Sciences brought in $379.6 million and Diagnostics $349.3 million, with Diagnostics shrinking on a reported basis because of the China business being sold. Both segments still expanded adjusted margins, which is where the growth came from.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-11
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.